A replay of the webcast Readouts for two late-stage, potentially registrational trials of nemvaleukin alfa expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for ...

The oncology business, meanwhile, would be biologics-focused and feature lead drug nemvaleukin alfa – an IL-2 therapy in phase 3 testing alongside Merck & Co's Keytruda (pembrolizumab ...

Today, we announced that based on the overall survival data observed in the interim analysis, we will not progress our phase 3 ARTISTRY-7 trial of nemvaleukin in combination with pembrolizumab in ...

BELLA trial evaluates relacorilant, nab-paclitaxel, and Avastin in platinum-resistant ovarian cancer patients across multiple regions. Phase 3 ROSELLA trial showed relacorilant improved ...

Forbes contributors publish independent expert analyses and insights.